Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00721669 · ClinicalTrials.gov registry record · Phase 1
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by ImmunoGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT00721669 is a Phase 1 study of Solid Tumor that has completed, run by ImmunoGen. The registered enrollment target is 60 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00721669, a Phase 1 study of Solid Tumor, has completed, sponsored by ImmunoGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
Primary objective is to evaluate the safety and PK of IMGN388
Conditions Studied
Interventions
- DRUG IMGN388
Study Locations (3)
Florida
- Florida Cancer Specialists - Fort Myers
Oklahoma
- University of Oklahoma - Oklahoma City
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00721669
The ClinicalTrials.gov registry entry for NCT00721669 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (73% lower). The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which IMGN388 is the first listed.
NCT00721669 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Oklahoma, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00721669 about?
NCT00721669 is a clinical study titled "A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors". Primary objective is to evaluate the safety and PK of IMGN388
What is the current status of trial NCT00721669?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2008-06. Estimated completion is 2012-12.
What conditions does trial NCT00721669 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT00721669?
The interventions under investigation include: IMGN388 (DRUG).
Who is sponsoring clinical trial NCT00721669?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00721669 being conducted?
This trial has 3 study locations across Florida, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.